MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021
MannKind Corporation (Nasdaq:MNKD) will announce its third quarter financial results on November 9, 2021, at 5:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MannKind Corporation (Nasdaq:MNKD) will announce its third quarter financial results on November 9, 2021, at 5:00 PM ET. CEO Michael Castagna and CFO Steven B. Binder will discuss the financial performance and corporate updates during a conference call. The call will be available for live listening on the company’s website, with a replay accessible for 14 days. MannKind specializes in developing inhaled therapeutic products, including Afrezza, the only FDA-approved inhaled ultra rapid-acting mealtime insulin in the U.S. More information can be found on their corporate site.
Positive
- MannKind continues to commercialize Afrezza, expanding availability in the U.S. and Brazil.
- The upcoming Q3 financial results may provide insights into the growth trajectory of Afrezza.
Negative
- None.
Details
News Market Reaction – MNKD
The recorded move for MNKD in the trading session of this news was +2.05%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, November 9, 2021.
Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven B. Binder.
Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at Events & Presentations https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available on MannKind's website for 14 days.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company’s partner, Biomm SA. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.
MANNKIND CONTACT:
Rose Alinaya, Investor Relations
Phone: (818) 661-5000
Email: ir@mannkindcorp.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.